retatrutide type 2 diabetes trial results 2024 2025 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of Retatrutide produces up to 30.3%
Pay in 4 interest-free payments of $6.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
























